Analysis of ethical dilemma
Case: In 2015, Turing Pharmaceuticals purchased the American marketing rights to Daraprim, the branded version of the drug known generically as pyrimethamine. The drug is on the World Health Organization’s List of Essential Medicines because it is used to treat the parasite infection toxoplasmosis, malaria, and is often used for people with compromised immune systems, including AIDS patients, as well as some cancer patients and elderly patients. After Turing purchased the rights to Daraprim, the company increased the price from $13.50 per tablet to $750 per tablet, raising the annual cost of treatment for some patients to hundreds of thousands of dollars.
Please take a look at the instruction I uploaded. Since this is a group paper, I ONLY need to focus on Question 4.
– “Did the participants in the case follow good business practices? In other words, did they make money? Does the business organization still exist?”
Please do some researches about that case. Thank you!
The links below are some articles I found on the Internet. You could use those articles as some resources.
https://www.forbes.com/sites/luketimmerman/2015/09/23/a-timeline-of-the-turing-pharma-controversy/?sh=615a867b771d
https://www.npr.org/sections/health-shots/2019/12/31/792617538/a-decade-marked-by-outrage-over-drug-prices
https://www.bbc.com/news/business-35136834
https://www.cnn.com/2020/02/29/health/daraprim-generic-version/index.html
‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High
